When was Apelix launched on the market?

Alpelisib (Alpelisib) is a drug for the treatment of breast cancer. It was launched in 2019 . Specifically, Apelvis obtained approval from the U.S. Food and Drug Administration (FDA) on May 24, 2019. ) as a targeted therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer harboring PIK3CA gene mutations. Apelis has not yet been launched in China, so it is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase Apelis through overseas channels. In foreign countries, the original Apelvis drug is mainly used. There are European and Indian versions of the original drug on the market. The price of the European version of the original drug is as high as tens of thousands of yuan. Relatively speaking, the price of the Indian version of the original drug is around four to five thousand yuan. The price is still relatively cheap. Moreover, the ingredients and efficacy of the European and Indian original drugs are consistent.